ONCOLOGICAL THERAPY THROUGH BIOLOGICAL INTERACTION NETWORK DISCOVERY
The oncological therapeutic strategies in recent years have targeted specific proteins and tried to modulate their activity to restore the normal operation of biochemical processes that are the base of the regulation of cellular proliferation. The adopted therapeutic approaches can act after the gene product or through an upstream action for the regulation of the gene expression or for the functionalization/de-functionalization of the RNA. Both therapeutic approaches target directly two different types of biological molecules (proteins and RNA, respectively), but have in common the fact that they act through the modulation of a biological interaction.
Therefore, the computational approach in the prediction of new therapies can be the same and, in both cases, we can take advantage of the analysis of a complete network interaction involving all the players in the system. However, to initiate this computational approach, it is necessary to establish a rationalized and integrated database as a starting point, to allow decisional workflow that pin-point new therapeutic strategies.
Hence this project’s goals are:
A. Rationalize the data of both identified scientific fields (medicinal chemistry and transcriptomic/proteomic)
B. Integration of the data from these two fields
C. Creation of a decisional ontology workflow
ACTIVITIES OF 2038 WITHIN THE OBIND PROJECT
2038 Innovation Company’s main goal is to develop and test the software components for the system’s proxy server, providing access control to the app and external applications. This module will provide registration, authentication, authorization and login systems for the platform’s users. Thus this layer will come between the RESTful requests from the users and the access to the data/services that the platform offers which, through established authentication/authorization policies, will allow a safe and controlled use of the platform, avoiding illegal accesses and guaranteeing the data integrity.
OBIND is co-financed by Programma Operativo FESR Regione Siciliana 2014/2020, Asse 1, Azione 1.1.5 “Sostegno all’avanzamento tecnologico delle imprese attraverso il finanziamento di linee pilota e azioni di validazione precoce dei prodotti e di dimostrazione su larga scala”.
Project code: 086202000366, CUP G29J18000700007
Partner: Exprivia, Fondazione RI.MED, IBIM-CNR, Secureproject.it, 2038 Innovation Company, Os2, Università degli Studi di Palermo
2038 INNOVATION COMPANY SRL
VIA ARCANGELO LEANTI, 16 - 90141 - PALERMO
REA: PA - 31426